Medicine
Granix 300 mcg/0.5 mL injection
Granix 300 mcg/0.5 mL injection is a prescription medicine containing Filgrastim for subcutaneous use, marketed by Cephalon, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store GRANIX in a refrigerator at 36°F to 46°F (2°C to 8°C). Within its shelf…
Key facts
- Active ingredient (INN)
- Filgrastim
- Brand
- Granix
- Strength
- 300 mcg/0.5 mL
- Dosage form
- Injection
- Route
- Subcutaneous
- Packs
- 1 blister pack of 0.5 mL, 10 blister pack of 0.5 mL, 1 syringe of 0.5 mL and 1 more
- Marketing authorisation holder
- Cephalon
- Manufacturer
- Cephalon
- Origin register
- US FDA, United States
- Storage
- Store GRANIX in a refrigerator at 36°F to 46°F (2°C to 8°C). Within its shelf life, the product may be removed from 36°F to 46°F (2°C to 8°C) storage for a single period of up to 5 days between 73°F to 81°F (23°C to 27°C). If not used within 5 days, the product may be returned to 36°F to 46°F (2°C to 8°C) up to the expiration date.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L03AA02 Filgrastim
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 11 November 2013
- Identifiers
- RxCUI 1433768, 1433771, 1442681 +5DailyMed set ID df918ec2-0907-443f-a52a-b72866959644NDC 63459-910Application BLA125294
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 blister pack in 1 carton / 1 syringe, glass in 1 blister pack / .5 mL in 1 syringe, glass | 63459-910-11 | Cephalon | 11 November 2013 |
| 10 blister pack in 1 carton / 1 syringe, glass in 1 blister pack / .5 mL in 1 syringe, glass | 63459-910-15 | Cephalon | 11 November 2013 |
| 1 syringe, glass in 1 carton / .5 mL in 1 syringe, glass | 63459-910-17 | Cephalon | 2 March 2015 |
| 5 syringe, glass in 1 carton / .5 mL in 1 syringe, glass | 63459-910-36 | Cephalon | 2 March 2015 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Filgrastim 300 mcg/0.5 mL injection.
- Zarxio 300 mcg/0.5 mL injectionAvailable on requestSandozUS FDA4 packs Cold chain
- Neupogen 300 mcg/0.5 mL injectionAvailable on requestAmgenUS FDA3 packs Cold chain
- Filkri 300 mcg/0.5 mL injectionAvailable on requestAccord BioPharmaIndiaUS FDA2 packs Cold chain
- Nivestym 300 mcg/0.5 mL injectionAvailable on requestPfizer LaboratoriesUS FDA2 packs Cold chain
- Releuko 300 mcg/0.5 mL injectionAvailable on requestAmneal PharmaceuticalsUS FDA2 packs Cold chain
Other strengths and forms of Filgrastim
Clinical summary
Filgrastim is a leukocyte growth factor indicated to Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever. MedsAcross supplies Filgrastim for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about FilgrastimFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- NEUPOGEN prescribing information (Amgen) · U.S. National Library of Medicine, DailyMed
- Accofil: European public assessment report (EPAR) · European Medicines Agency
- Filgrastim Hexal: European public assessment report (EPAR) · European Medicines Agency
Need Granix 300 mcg/0.5 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.